Non-melanoma skin cancer in renal transplant recipients: a study in a Brazilian reference center

Figures & data

Table 1 Distribution of epidemiological data

Variable	Category	Number of patients	% of total patients
Sex	Male	90	54.5
	Female	75	45.5
Race	White	68	41.2
	Mixed	71	43.0
	Black	26	15.8
Age (years)*	41.4±13.3 (44: 12–68)
Follow-up time (months)*	72.7±12.9 (75: 13–87)

Note:

* Mean ± standard deviation (median: minimum–maximum value).

Table 2 Epidemiological variable comparison for presence or absence of NMSC

Variable	Category	With NMSC (n=11)		With NMSC (n=154)		P-valuea
		N	%	N	%
Sex	Male	8	72.7	82	53.3	0.21
	Female	3	27.3	72	46.8
Race	White	8	72.7	60	39.0	0.030
	Mixed/black	3	27.3	94	61.0
Age bracket	<40 years	1	9.1	64	41.6	0.028
(1)	≥40 years	10	90.9	90	58.4
Age bracket	<50 years	6	54.5	109	70.8	0.21
(2)	≥50 years	5	45.5	45	29.2
Age (years)*		51.8±8.9		40.7±13.3		0.011
		49 (39–68)		43 (12–67)

Notes:

a Chi square test or Fisher’s exact test;

* mean ± standard deviation, median (minimum–maximum values).

Abbreviation: NMSC, non-melanoma skin cancer.

Table 3 Distribution of the NMSC characteristics

Variable	Category	n	%
Histologic subtype	BCC	9	47.4
	SCC	10	52.6
Site	Abdomen	1	5.3
	Forearm	3	15.8
	Scalp	2	10.5
	Leg	1	5.3
	Face	4	21.1
	Hand	1	5.3
	Arm	2	10.5
	Trunk	5	26.3
Sun-exposed site	Yes	12	63.2
	No	7	36.8
Time for NMSC (months)	37.7±19.1 (34: 3–78)*

Note:

* Mean ± standard deviation (median: minimum–maximum value).

Abbreviations: BCC, basal cell carcinoma; NMSC, non-melanoma skin cancer; SCC, squamous cell carcinoma.

Table 4 Immunosuppression drugs distribution

Drugs	With NMSC (n=11)		Without NMSC (n=154)
	n	%	n	%
CsA + Pred	0	0	1	0.65
FK + Pred	0	0	2	1.3
MM + Pred	1	9.1	10	6.5
SM + Pred	0	0	1	0.65
Sir + Pred	0	0	11	7.1
Sir + MM	0	0	3	2.0
MM + CsA + Pred	0	0	3	2.0
MM + FK + Pred	4	36.4	35	22.7
Sir + CsA + Pred	0	0	5	3.3
Sir + FK + Pred	1	9.1	12	7.8
Sir + MM + Pred	4	36.4	58	37.7
Sir + SM + Pred	1	9.1	10	6.5
Sir + MM + CsA	0	0	1	0.65
Sir + MM + FK + Pred	0	0	2	1.3

Abbreviations: CsA, cyclosporine; FK, tacrolimus; MM, mycophenolate mofetil; NMSC, non-melanoma skin cancer; Pred, prednisone; Sir, sirolimus; SM, sodic mycophenolate.